-  Nasopharyngeal carcinoma;<br/><br/>          -  R2 resection;<br/><br/>          -  Invalid informed consent;<br/><br/>          -  Performance Status > 1;<br/><br/>          -  Previous chemotherapy or radiotherapy for carcinoma of the head and neck;<br/><br/>          -  Prior exposure to EGFR pathway targeting therapy;<br/><br/>          -  Other serious illness or medical conditions:<br/><br/>               -  Unstable cardiac disease despite treatment, congestive heart failure NYHA grade<br/>                  3 and 4;<br/><br/>               -  Clinically significantly abnormal electrocardiogram (ECG) or left ventricular<br/>                  ejection fraction (LVEF) below the institutional range of the normal<br/><br/>               -  Significant neurologic or psychiatric disorders including dementia or seizures;<br/><br/>               -  Active uncontrolled infection;<br/><br/>               -  Active disseminated intravascular coagulation;<br/><br/>               -  Other serious underlying medical conditions which could impair the ability of<br/>                  the patient to participate in the study;<br/><br/>          -  Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria<br/>             (NCI-CTC v3.0) grade 2 or ototoxicity grade 2, except if due to trauma or mechanical<br/>             impairment due to tumor mass;<br/><br/>          -  Having participated in another therapeutic clinical trial or any investigational<br/>             agent in the preceding 30 days;<br/><br/>          -  Known allergic/hypersensitivity reaction to any of the components of the treatment;<br/><br/>          -  Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding;<br/><br/>          -  Known drug abuse;<br/><br/>          -  Other previous malignancy within 5 years, with exception of a history of a previous<br/>             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;<br/><br/>          -  Legal incapacity or limited legal capacity;<br/><br/>          -  Sensitivity and incompatibility against 5-Fluorouracil<br/><br/>          -  Sensitivity and incompatibility against platinum-compounds<br/><br/>          -  Known incompatibilities >grade 3 towards cetuximab<br/><br/>          -  expected incompliance of patient (e.g. in case of severe alcohol addiction)<br/><br/>          -  Dental evaluation: Pre treatment dental care before start of radiochemotherapy<br/>             (approximately 8 to 10 days lapse-time is needed for complete recovery before<br/>             initiation of radiation therapy).<br/>